Covid 19 Research using Clinical Trials (Home Page)
Report for D008175: Lung Neoplasms NIH
(Synonyms: Lung N, Lung Ne, Lung Neo, Lung Neop, Lung Neopl, Lung Neopla, Lung Neoplas, Lung Neoplasms)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug649 | INC424 / Ruxolitinib Wiki | 0.71 |
| drug657 | IgG test Wiki | 0.71 |
There are 2 clinical trials
Clinical Trials
1 Observational Retrospective Register of Spanish Lung Cancer Patients With COVID19 Disease
This is a multi-centre study on lung cancer patients which experienced COVID-19. Information on clinical features, clinical course, management and outcomes will be collected for both, thoracic cancers and COVID-19 infection. Firstly, investigators will be registered in an online secure registry. After that, a protocol will be developed in order to collect clinical data for the research. It will also include I on the care organization or the perception of the patient and their family members. The final stage will consist on retrospective data collection from patients. So, it is a retrospective study data collection, preceded by prospective data registry.
NCT04344002 Covid-19 Lung Cancer MeSH:Lung Neoplasms
HPO:Neoplasm of the lung
Primary Outcomes
Description: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as clinical data.
Measure: Clinical data of lung cancer patients with COVID-19 diagnoses Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years
Description: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as data about diagnosis
Measure: Diagnosis data Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years
Description: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as treatments received
Measure: Treatments received Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years
Description: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as prognostic factors.
Measure: Prognostic factors Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years
2 Study of Acquired Immunity in Patients With Lung Cancer and COVID-19 Infection
Primary Outcomes
Description: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as clinical data.
Measure: Clinical data of lung cancer patients with COVID-19 diagnoses Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 yearsDescription: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as data about diagnosis
Measure: Diagnosis data Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 yearsDescription: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as treatments received
Measure: Treatments received Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 yearsDescription: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as prognostic factors.
Measure: Prognostic factors Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 yearsObservational, retrospective data collection and prospective IgG analysis, and multicenter study. The main objective of the study is th description of the characteristics and evolution of patients with lung cancer who have acquired COVID-19 infection. For the identification of patients who contract COVID-19 infection, the IgG+ blood test by ELISA method will be used.
NCT04407143 Lung Cancer COVID Corona Virus Infection Diagnostic Test: IgG test MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Lung Neoplasms
HPO:Neoplasm of the lung
Primary Outcomes
Description: Description of the characteristics and evolution of patients with lung cancer who have contracted COVID-19 infection.
Measure: Description of the characteristics of patients Time: From the diagnosis of the COVID until the determination of the blood IgGs, up to 10 weeks
HPO Nodes
HP:0100526: Neoplasm of the lung
Genes 62
TP53 SLCO2A1 STAT6 WT1 BRAF HPGD TSC1 PRKN CYP2A6 PPP2R1B LMNA MUC5B PIK3CA DIS3L2 CASP8 STK11 H19 BRCA2 NOTCH3 WT1 SFTPA2 TSC2 FASLG BAP1 WRN ERCC6 MBTPS2 DICER1 C11ORF95 TRIM28 RB1 GPC3 RELA PERP SFTPC SLC22A18 PDGFRB ERBB2 TSC2 PTEN TRIP13 EWSR1 MAP3K8 TSC1 TRPV3 DICER1 TERT TRIM28 IRF1 REST TSC1 TP53 KEAP1 DICER1 AKT1 KRAS POU6F2 NAB2 TSC1 WT1 EGFR TSC2 Protein Mutations 52
C1156Y C797S D594G F1174C F1174V G1202R G1269A G12C G12D G469A G719A G719C G719S G776C G776V I10A L1196M L1198F L523S L755S L833F L8585R L858R L859R L861G L861Q L861R N375S P13K P4503A R776G R831C S1400A S1400C S1400D S1400E S1400F S1400G S1400I S1400K S1800A S1900A S1900C S1900D S768I T790M T81C T890M V600E V769L V777L V843I
Primary Outcomes
Description: Description of the characteristics and evolution of patients with lung cancer who have contracted COVID-19 infection.
Measure: Description of the characteristics of patients Time: From the diagnosis of the COVID until the determination of the blood IgGs, up to 10 weeks